Ligand Pharmaceuticals is seeing a notable increase in its stock price, driven by strategic acquisitions and positive market sentiment.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is up today, with shares rising by 1.12% to close at CA$301.76. This gain follows significant news about the company's recent acquisition of royalty rights for the pediatric myopia treatment, Ryjunea®.
Advertisement
Ligand Pharmaceuticals Incorporated
LGND.US
LGND.US
Ligand Pharmaceuticals Incorporated
WealthAwesomeMarket cap
$5.95B
P/E
30.7x
52W high
$326.63
52W low
$166.10
1W change
+8.43%
Beta
0.98
Analyst Price Targets
Based on 7 analysts covering LGND · as of Sep 17, 2026
Wall Street analysts forecast LGND stock price to rise 14.9% over the next 12 months.
Consensus
Strong Buy4.57 / 5.00
Avg. Target
C$342.82
+14.9% Upside
Current Price
C$298.41
Last close
Analyst Breakdown (7 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LGND's historical volatility
30-Day Vol
25.0%
Annualized
90-Day Vol
34.0%
Annualized
Trend (90d)
-7.2%
Annualized drift
90d Mean
C$290.81
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$295.85 | C$271.44 – C$322.47 |
| 60 trading days | C$293.32 | C$259.68 – C$331.32 |
| 90 trading days | C$290.81 | C$250.50 – C$337.59 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider how Ligand's latest acquisition could boost its revenue streams and strengthen its position in the pediatric ophthalmology sector.
Ligand Pharmaceuticals Secures $23 Million Royalty Agreement
The $23 million upfront payment for Ryjunea® underscores Ligand's commitment to expanding its royalty portfolio in a high-demand therapeutic area.
Bull case
Acquiring the royalty rights for Ryjunea® positions Ligand to take advantage of the growing need for treatments for pediatric myopia. This could lead to increased revenue and greater value for shareholders.
Bear case
Despite this positive development, investors should stay cautious about market volatility and the risks involved in integrating new assets into Ligand's portfolio.
Advertisement
Strategic Acquisition Boosts Ligand's Portfolio
Ligand Pharmaceuticals announced its acquisition of royalty rights for Ryjunea®, a treatment aimed at slowing the progression of pediatric myopia. The company made a $23 million upfront payment to Sydnexis, allowing Ligand to earn tiered royalties on net sales in Europe, the Middle East, and Africa. This strategic move is expected to enhance Ligand's revenue potential as the demand for effective pediatric treatments continues to grow.
Market Response and Future Outlook
The market has reacted positively to Ligand's acquisition news, reflecting investor confidence in the company's ability to leverage its new asset. As myopia becomes a significant health concern among children globally, Ligand's entry into this market could result in substantial revenue growth. However, investors are advised to keep a close eye on ongoing developments and market conditions to evaluate the sustainability of this upward trend.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
